As an alternative therapy for the management of non-infectious uveitis, the use of Anti IL6 (tocilizumab or sarilumab), anti CD20 (rituximab) or Anti IL17 (secukinumab) has been tested in small case series, and a favorable response has been observed, although clinical trials are still pending [16–18]. The gene discussed is IL17A; the disease is uveitis.